Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Next Previous
Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilvegostomig (Primary) ; Capecitabine; Cisplatin; Gemcitabine; Gimeracil/oteracil/tegafur
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ARTEMIDE-(Biliary01); ARTEMIDE-Bil01
  • Sponsors AstraZeneca

Most Recent Events

  • 04 Jun 2024 Trial design assessing the efficacy and tolerability of rilvegostomig IV every three weeks versus placebo in combination with investigator's choice of chemotherapy (capecitabine, S-1 [tegafur/gimeracil/oteracil] or gemcitabine/cisplatin) as adjuvant treatment in patients with BTC after curative intent resection were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 02 Apr 2024 Planned End Date changed from 24 Sep 2030 to 30 Sep 2030.
  • 02 Apr 2024 Planned primary completion date changed from 25 Jun 2029 to 29 Jun 2029.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top